Reports Q3 revenue $83.52M, consensus $82.9M. “This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics,” said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne (BLLN). “The incredible strength and momentum across our prenatal and oncology businesses reflects a deliberate commitment to scientific rigor paired with resourceful, step-by-step execution. We continue to earn the trust of providers, patients, payors, and health systems, and rapidly grow our test volumes by solving unmet clinical needs. As we begin our path as a public company, we remain guided by the same principles we started with-relentless focus and an unwavering commitment to re-defining molecular diagnostics.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN:
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
- BillionToOne initiated with an Outperform at William Blair
- BillionToOne initiated with a Buy at BTIG
- BillionToOne: A High-Growth Leader in Prenatal Genetics and Oncology with Strong Buy Rating
- BillionToOne initiated with an Equal Weight at Wells Fargo